Streetbeat News

Regulatory

AAPL

Apple Inc. (AAPL) is currently in two bullish patterns, indicating a likely short-term positive trend. The patterns, a rising channel and an inside bar formation, suggest a period of consolidation followed by a continuation in the direction of the current trend. However, the upcoming Federal Reserve decision on interest rates may increase market volatility. Apple's stock has been in a consistent uptrend since March 2, with resistance above at $194.48 and $200, and support below at $189.61 and $182.94.

Portfolio Pulse from Melanie Schaffer

July 19, 2023 | 12:50 pm

MGTX

MeiraGTx Holdings plc (MGTX) has announced that its wholly-owned gene therapy manufacturing facility in Shannon, Ireland has received commercial MIA authorization for QC testing. This authorization will allow the company to conduct quality control testing of its gene therapy products in-house, potentially speeding up the production process.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:35 pm

TENX

Tenax Therapeutics has been granted a U.S. patent for oral Levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), a condition affecting over 1.6 million North Americans. The patent provides intellectual property protection until December 2040 and may qualify for term extension beyond 2040. The company plans to initiate a Phase 3 trial using TNX-103 (oral levosimendan) in 2023.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:31 pm

SPY

The number of building permits issued in the USA for June was 1.440 million, lower than the estimated 1.490 million and the prior figure of 1.496 million.

Portfolio Pulse from Happy Mohamed

July 19, 2023 | 12:30 pm

GOOG

GOOGL

Google, owned by Alphabet Inc, has clarified that the recent Indian court's directive preventing the removal of Disney's local streaming service, Disney+ Hotstar, from the Play Store is only temporary. Google will impose a temporary 4% fee on in-app purchases until the conclusion of the legal proceedings. The court also directed Novi Digital, the company behind the streaming service, to pay a 4% commission to Google for in-app purchases. This lawsuit marks the most prominent challenge against Google's new 'service fee' policy in India.

Portfolio Pulse from Shomik Sen Bhattacharjee

July 19, 2023 | 12:26 pm

KPTI

Karyopharm has announced an updated exploratory subgroup analysis from its SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer. The data will be presented at the ASCO Plenary Series on July 25th. This supports the company's ongoing Phase 3 study evaluating Selinexor as a maintenance therapy following systemic therapy in these patients.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:06 pm

HOTH

Hoth Therapeutics, Inc. (NASDAQ:HOTH) has received FDA approval for a protocol change in its Phase 2a clinical trial of HT-001, a cancer therapeutic. The trial will now be conducted at two approved sites, with additional sites in the approval process. The study will be completed in two parts, with the first part being an open-label cohort and the second part being a randomized, placebo-controlled, parallel Phase 2a dose-ranging study.

Portfolio Pulse from Happy Mohamed

July 19, 2023 | 12:05 pm

TPST

Tempest Therapeutics has announced that its drug TPST-1495 has shown increased potency against prostaglandin-driven tumor models by blocking EP2 and EP4 receptors. The drug's anti-tumor response is both immune dependent and immune independent. These preclinical findings support the previously reported Phase 1 clinical results for TPST-1495, which showed tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 12:04 pm

JAQC

Shares of Jupiter Acquisition Corporation have been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 11:56 am

BMY

JNJ

MRK

Johnson & Johnson (JNJ) has joined other pharmaceutical companies in legal action against the U.S. government over a program that allows Medicare to negotiate lower drug prices. The pharmaceutical sector argues that the program will limit profits and hinder the development of new treatments. The Biden administration expects the program to save $25 billion annually by 2031. Other companies involved in legal action against the program include Bristol Myers Squibb (BMY) and Merck & Co (MRK).

Portfolio Pulse from Vandana Singh

July 19, 2023 | 11:48 am